KIT and gastrointestinal stromal tumor: The study showed that compared with imatinib and sunitinib, nintedanib was more potent against GIST‐T1 cells (GI50 = 1.7 nm; Fig. 2A), which harbour the Δ560–578 mutation in the juxtamembrane region of KIT.